{"url_path":"/sec/qure/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **                        **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1590560/0001104659-26-076044-index.html","accession_number":"0001104659-26-076044","cik":"0001590560","ticker":"QURE","issuer_name":"uniQure N.V.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1590560/0001104659-26-076044-index.html","primary_entity_key":"0001590560","primary_entity_name":"uniQure N.V."},"word_count":172,"has_tables":true,"body_markdown":"**Item 7.01**                        **Regulation FD Disclosure.**\n\nOn June 19, 2026, uniQure N.V. (the “**Company**”) issued a press release announcing preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n​\n\nThe information provided in this Item 7.01, including the accompanying Exhibit 99.1, shall be deemed “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), or otherwise subject to the liability of such section, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except to the extent that such filing incorporates by reference any or all of such information by express reference."}